Tag - Andre Uddin

Markets

Mackie cuts Cipher Pharma PT to $1 from $2.30

Mackie Research lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $1 (Canadian) from $2.30, citing a delay in the out-licensing of its Canadian assets because of a dispute with Bausch Health (NYSE:BHC)...

March 27, 2020

Markets

Mackie Research ups Profound Medical to speculative buy

Mackie Research upgraded Profound Medical (TSX:PRN; NASDAQ:PROF) to “speculative buy” from “hold,” but reduced its price target to $16.20 from $26.10 due to the anticipated impact of the coronavirus. The stock closed at...

March 24, 2020

Markets

Analysts downgrade Correvio Pharma as FDA Adcom rejects Brinavess

Analysts for H.C. Wainwright, Mackie Research and Echelon Wealth Partners downgraded Correvio Pharma (NASDAQ:CORV) after the FDA Cardiovascular and Renal Drugs Advisory Committee voted 11-2 against recommending approval...

December 11, 2019

Markets

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

Mackie Research upgraded Theratechnologies (TSX:TH; NASDAQ:THTX) to “buy” from “hold” but maintained its price target at $6.50 (Canadian), saying the current share price represents a favorable risk-reward situation...

December 11, 2019

Markets

Mackie ups Knight Therapeutics to buy; PT to $10.80 from $8.20

Mackie Research Capital upgraded Knight Therapeutics (TSX:GUD) to “buy” from “hold” and raised its price target to $10.80 from $8.20 after Knight’s planned acquisition of Grupo Biotoscana for $369-million (Canadian)...

October 23, 2019

Markets

Mackie starts Acerus Pharma at speculative buy; PT 50 cents

Mackie Research Capital initiated coverage of Acerus Pharmaceuticals (TSX:ASP) with a “speculative buy” rating and a 12-month target price of 50 cents. The stock closed at 26 cents on March 13. Acerus specializes in men...

March 14, 2018

Tag - Andre Uddin

Mackie cuts Cipher Pharma PT to $1 from $2.30

Mackie Research ups Profound Medical to speculative buy

Analysts downgrade Correvio Pharma as FDA Adcom rejects Brinavess

Mackie Research ups Theratechnologies to buy; holds PT at $6.50

Mackie ups Knight Therapeutics to buy; PT to $10.80 from $8.20

Mackie starts Acerus Pharma at speculative buy; PT 50 cents

General

More